



August 6, 2014

Chembio to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, August 7, 2014

Category: Baystreet Newswire

Company: Issuer Direct

ID: 418805

Date: Wednesday, August 06, 2014

Ticker: NASDAQ:CEMI

MEDFORD, NY / ACCESSWIRE / August 6, 2014 / Chembio Diagnostics, Inc. (NASDAQ:CEMI) will host a conference call and live webcast to discuss the results of the second quarter 2014, to be held Thursday, August 7, 2014 at 10:00 AM Eastern Time. To participate in this event, dial 877-407-0778 domestically, or 201-689-8565 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=173033 as well as via the Chembio website (www.chembio.com). If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com/ClientPage.asp?ID=173033 or www.chembio.com. You may access the teleconference replay by dialing 877-660-6853 domestically or 201-612-7415 internationally, referencing conference ID #13587650. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on August 14, 2014. About Chembio Diagnostics Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing \$10 billion point-of-care testing market. Chembio markets its HIV 1/2 STAT-PAK(R) Assay to physicians and testing sites in the U.S. and through select distributor channel partners. The Company's SURE CHECK(R) HIV 1/2 Assay is marketed exclusively in the U.S. by Alere, Inc. Chembio also markets its HIV 1/2 STAT-PAK(R) and SURE CHECK(R) HIV 1/2 Assays internationally through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP(R)) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products. Headquartered in Medford, NY, with approximately 200 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Chembio Diagnostic Systems, Inc. is a wholly-owned subsidiary of Chembio Diagnostics, Inc. For more information, please visit: www.chembio.com. SOURCE: Chembio Diagnostics, Inc.

News Provided by Acquire Media